Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Imprivata Inc | d768479d8k.htm |
Exhibit 99.1
Imprivata, Inc. Reports Second Quarter 2014 Financial Results
Key Accomplishments:
| • | Successfully completed an initial public offering of our common stock. Imprivata sold 5.75 million shares for net proceeds of $80.2 million, excluding offering expenses. |
| • | Revenues for the second quarter were $23.2 million, a 34% increase from the same period in 2013. |
| • | Imprivata hosted its annual worldwide user conference, HealthCon, in Boston, Massachusetts. Over 120 CIOs and Senior IT and clinical leaders attended, with 18 of the Company’s key technology partners co-sponsoring the event. |
| • | Announced July 31, 2014, Imprivata OneSign leads the KLAS 2014 Mid-Term Performance Review in the single sign-on category. |
Lexington, Mass. — (BUSINESS WIRE) — August 4, 2014 — Imprivata® (NYSE: IMPR), a leading provider of authentication and access management solutions for the healthcare industry, today announced financial results for the second quarter of fiscal 2014. Revenues for the second quarter were $23.2 million, an increase of 34% from revenues of $17.3 million for the same period in 2013. Revenues for the six months ended June 30, 2014 were $42.7 million, an increase of 35% from revenues of $31.6 million for the same period in 2013.
Omar Hussain, CEO of Imprivata, commented, “We are pleased to report that our second quarter results exceeded our plan and that we continue to see increasing demand for our solutions as hospitals globally continue to spend to address clinician productivity and regulatory challenges. Our first quarter as a public company showed solid revenue growth driven both by new customers and add on sales to existing customers.”
Net loss for the second quarter of 2014 was $3.6 million, or $(1.08) per basic and diluted share, as compared to a net loss of $84,000, or $(0.41) per basic and diluted share for the same period in 2013. Net loss for the six months ended June 30, 2014 was $10.6 million, or $(3.25) per basic and diluted share, as compared to a net loss of $1.6 million, or $(1.28) per basic and diluted share for the same period in 2013.The increase in the net loss between the periods presented reflects our strategic investments in the business to maintain our market leadership position and capture additional market share, as well as develop new complementary products to our existing product portfolio.
Adjusted EBTIDA(1) for the second quarter of 2014 was a loss of $2.8 million, as compared to income of $644,000 for the same period in 2013. Non-GAAP net loss (2) for the second quarter of 2014 was $3.6 million, or $(0.81) per basic and diluted share, as compared to non-GAAP net income of $116,000, or $0.04 per basic share and $0.01 per diluted share, for the same period in 2013. Adjusted EBTIDA for the six months ended June 30, 2014 was a loss of $8.7 million, as compared to a loss of $177,000 for the same period in 2013. Non-GAAP net loss for the six months ended June 30, 2014 was $10.2 million, or $(2.53) per basic and diluted share, as compared to non-GAAP net loss of $1.1 million, or $(0.33) per basic and diluted share, for the same period in 2013. A reconciliation of GAAP to these non-GAAP financial measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”
| (1) | Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability. |
| (2) | Non-GAAP net income (loss) and non-GAAP net income (loss) per share excludes amortization of purchased intangible assets, stock-based compensation and the impact of the fair value revaluation on our contingent liability. |
Third Quarter and Full-Year 2014 Financial Outlook
For the full-year, we expect revenue between $91 million and $93 million and adjusted EBITDA to be between a loss of $14 million and $12 million. In terms of earnings per share, we expect GAAP loss to be between $1.28 per share and $1.20 per share and non-GAAP loss, which adjusts for stock-based compensation, amortization of purchased intangible assets and the contingent liability revaluation, to be between $1.18 per share and $1.10 per share. Our annual EPS estimates are based on an estimated weighted average-share count of 13.9 million.
For the third quarter, we expect revenue between $23 million and $24 million and adjusted EBITDA to be between a loss of $3.5 million and $2.5 million. In terms of earnings per share, we expect GAAP loss to be between $0.19 per share and $0.16 per share and non-GAAP loss to be between $0.17 per share and $0.14 per share. Our third quarter EPS estimates are based on an estimated weighted average-share count of 23.7 million.
Conference Call Information
Imprivata management will host a conference call at 5:00 pm (Eastern Time) on Monday, August 4, 2014 to discuss the second quarter results and other matters. The conference call will be accessible by dialing 877-270-2148, or 412-902-6510 for international callers, and referencing “Imprivata 2nd Quarter”. A live webcast of the conference call will also be available on the investor relations section of the company’s website at www.imprivata.com.
An audio replay will be available following the conclusion of the call through November 5, 2014. The replay can be accessed by dialing (877) 344-7529 in the U.S., or +1 (412) 317-0088 for international callers. The passcode for the replay is: 10049678.
About Imprivata
Imprivata, Inc. (NYSE: IMPR) headquartered in Lexington, Massachusetts, is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s flagship solution, Imprivata OneSign®, is an integrated enterprise single sign-on, authentication and access management and workflow automation platform that addresses multiple security and productivity challenges faced by hospitals and other healthcare organizations. For more information, please visit www.imprivata.com.
Investor relations:
Bob East
Westwicke Partners, LLC
(443) 213-0503
Bob.east@westwicke.com
imprivata@westwicke.com
Public relations:
Caitlin Hunt
MSL Group
(781) 684-0770
imprivata@mslgroup.com
All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity for growth in our customer base and our overall business, our market opportunity, our goal to maintain market leadership and our expected financial results for Q3 2014 and the full fiscal year 2014. All statements other than statements of historical fact contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “could,” “increases,” “improves,” “reduces,” “implements,” “results,” “addresses,” or the negative of these terms or other comparable terminology. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Imprivata’s control. Imprivata’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, our ability to successfully develop and introduce new solutions and products for existing solutions; our ability to attract new customers and retain and increase sales to existing customers; developments in the healthcare industry or regulatory environment; seasonal variations in the purchasing patterns of our customers; the lengthy and unpredictable sales cycles for new customers; our ability to maintain successful relationships with our channel partners and technology alliance partners; our dependency on sole source suppliers and a contract manufacturer for hardware components of our Imprivata OneSign solution; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of protected health information; our ability to protect our intellectual property rights, and the other risks detailed in Imprivata’s risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to Imprivata’s Registration Statement on Form S-1 declared effective by the SEC on June 24, 2014, as well as other documents that may be filed by Imprivata from time to time with the SEC. The forward-looking statements included in this press release represent Imprivata’s views as of the date of this press release. Imprivata undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Non-GAAP Financial Measures
Imprivata has provided in this release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA, non-GAAP net income (loss) and non-GAAP net income (loss) per share. These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Imprivata believes that the use of these non-GAAP financial measures provides supplementary information for investors to use in evaluating operating performance and in comparing its financial measures with other companies in Imprivata’s industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA (EBITDA adjusted for foreign currency gains (losses), stock based-compensation and the impact of the fair value revaluation on our contingent liability), non-GAAP net income (loss) and non-GAAP net income (loss) per share exclude amortization expense associated with our purchased intangible assets, stock-based compensation and the impact of the re-measurement to fair value of our contingent liability. Non-GAAP financial measures that Imprivata uses may differ from measures that other companies may use. These non-GAAP financial measures disclosed by Imprivata are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.
Imprivata, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenue |
||||||||||||||||
| Product |
$ | 12,225 | $ | 9,558 | $ | 21,499 | $ | 16,906 | ||||||||
| Maintenance and services |
11,008 | 7,757 | 21,175 | 14,664 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
23,233 | 17,315 | 42,674 | 31,570 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cost of revenue |
||||||||||||||||
| Product |
2,475 | 1,593 | 4,635 | 3,170 | ||||||||||||
| Maintenance and services |
4,400 | 2,508 | 8,593 | 4,746 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total cost of revenue |
6,875 | 4,101 | 13,228 | 7,916 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
16,358 | 13,214 | 29,446 | 23,654 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses |
||||||||||||||||
| Research and development |
6,291 | 4,452 | 12,827 | 8,453 | ||||||||||||
| Sales and marketing |
11,216 | 7,201 | 21,635 | 13,459 | ||||||||||||
| General and administrative |
2,311 | 1,596 | 5,324 | 3,369 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
19,818 | 13,249 | 39,786 | 25,281 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(3,460 | ) | (35 | ) | (10,340 | ) | (1,627 | ) | ||||||||
| Other income (expense) |
||||||||||||||||
| Interest and other (expense) income, net |
(31 | ) | (5 | ) | (192 | ) | 54 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income taxes |
(3,491 | ) | (40 | ) | (10,532 | ) | (1,573 | ) | ||||||||
| Income taxes |
61 | 44 | 87 | 41 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
(3,552 | ) | (84 | ) | (10,619 | ) | (1,614 | ) | ||||||||
| Accretion of redeemable convertible preferred stock |
(1,204 | ) | (1,238 | ) | (2,442 | ) | (2,476 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to common stockholders |
$ | (4,756 | ) | $ | (1,322 | ) | $ | (13,061 | ) | $ | (4,090 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to common stockholders |
||||||||||||||||
| Basic and diluted |
$ | (1.08 | ) | $ | (0.41 | ) | $ | (3.25 | ) | $ | (1.28 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders |
||||||||||||||||
| Basic and diluted |
4,410 | 3,250 | 4,021 | 3,186 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Imprivata, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
| June 30, | December 31, | |||||||
| 2014 | 2013 | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 85,794 | $ | 13,284 | ||||
| Accounts receivable, net of allowances |
13,978 | 19,754 | ||||||
| Prepaid expenses and other current assets |
3,486 | 2,541 | ||||||
|
|
|
|
|
|||||
| Total current assets |
103,258 | 35,579 | ||||||
| Property and equipment, net |
7,740 | 6,682 | ||||||
| Goodwill |
1,560 | 1,560 | ||||||
| Intangible assets, net |
1,744 | 2,000 | ||||||
| Other assets |
109 | 649 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 114,411 | $ | 46,470 | ||||
|
|
|
|
|
|||||
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 3,599 | $ | 3,586 | ||||
| Accrued expenses and other current liabilities |
7,778 | 9,149 | ||||||
| Current portion of capital lease obligations and long-term debt |
665 | 313 | ||||||
| Current portion of other long-term liabilities |
288 | 249 | ||||||
| Current portion of deferred revenue |
25,646 | 25,084 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
37,976 | 38,381 | ||||||
| Deferred revenue, net of current portion |
4,266 | 3,490 | ||||||
| Capital lease obligations, long-term debt and royalty obligations, net of current portion |
888 | 410 | ||||||
| Other long-term liabilities, net of current portion |
1,225 | 1,181 | ||||||
| Contingent purchase price liability |
544 | 1,008 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
44,899 | 44,470 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Redeemable convertible preferred stock |
— | 91,607 | ||||||
| Stockholders’ equity (deficit): |
||||||||
| Undesignated preferred stock |
— | |||||||
| Common stock |
24 | 4 | ||||||
| Additional paid-in capital |
170,921 | — | ||||||
| Accumulated other comprehensive income (loss) |
1 | (145 | ) | |||||
| Accumulated deficit |
(101,434 | ) | (89,466 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity (deficit) |
69,512 | (89,607 | ) | |||||
|
|
|
|
|
|||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
$ | 114,411 | $ | 46,470 | ||||
|
|
|
|
|
|||||
Imprivata, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Six Months Ended June 30, |
||||||||
| 2014 | 2013 | |||||||
| Cash flows from operating activities: |
||||||||
| Net Loss |
$ | (10,619 | ) | $ | (1,614 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Depreciation and amortization expense |
1,458 | 1,163 | ||||||
| Provision for doubtful accounts |
13 | — | ||||||
| Stock-based compensation |
665 | 257 | ||||||
| Loss on disposal of fixed assets |
12 | 14 | ||||||
| Change in value of contingent purchase price liability |
(464 | ) | 31 | |||||
| Changes in operating assets and liabilities |
||||||||
| Accounts receivable |
5,763 | 5,083 | ||||||
| Prepaid expenses and other current assets |
(544 | ) | (278 | ) | ||||
| Other assets |
— | (1 | ) | |||||
| Deferred revenue |
1,338 | (1,015 | ) | |||||
| Accounts payable |
(897 | ) | (1,606 | ) | ||||
| Accrued expenses and other current liabilities |
(1,549 | ) | (2,708 | ) | ||||
| Other liabilities |
82 | (128 | ) | |||||
|
|
|
|
|
|||||
| Net cash used in operating activities: |
(4,742 | ) | (802 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from investing activities: |
||||||||
| Purchases of property and equipment |
(1,354 | ) | (720 | ) | ||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(1,354 | ) | (720 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from financing activities: |
||||||||
| Proceeds from initial public offering, net of underwriting discounts and commissions |
80,213 | — | ||||||
| Deferred offering costs |
(1,748 | ) | — | |||||
| Repayments for capital lease obligations, long-term debt and other |
(348 | ) | (181 | ) | ||||
| Proceeds from exercise of stock options |
389 | 765 | ||||||
|
|
|
|
|
|||||
| Net cash provided by financing activities |
78,506 | 584 | ||||||
|
|
|
|
|
|||||
| Effect of exchange rates on cash and cash equivalents |
100 | (258 | ) | |||||
|
|
|
|
|
|||||
| Net increase (decrease) in cash and cash equivalents |
72,510 | (1,196 | ) | |||||
| Cash and cash equivalents, beginning of period |
13,284 | 15,410 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents, end of period |
$ | 85,794 | $ | 14,214 | ||||
|
|
|
|
|
|||||
Imprivata, Inc.
Non-GAAP Financial Measures
(In thousands, except per share amounts)
(Unaudited)
Reconciliation of GAAP Net Loss to Adjusted EBITDA
| Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| GAAP net loss |
$ | (3,552 | ) | $ | (84 | ) | $ | (10,619 | ) | $ | (1,614 | ) | ||||
| Adjustments to reconcile to Adjusted EBITDA: |
||||||||||||||||
| Income tax expense |
61 | 43 | 87 | 41 | ||||||||||||
| Depreciation and amortization |
763 | 608 | 1,458 | 1,163 | ||||||||||||
| Other expense (income), net |
31 | 5 | 192 | (55 | ) | |||||||||||
| Stock-based compensation |
367 | 140 | 665 | 257 | ||||||||||||
| Change in fair value of contingent liability |
(509 | ) | (68 | ) | (464 | ) | 31 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | (2,839 | ) | $ | 644 | $ | (8,681 | ) | $ | (177 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
Reconciliation of GAAP Net Loss to Non-GAAP Net (Loss)
Income and Non-GAAP Net (Loss) Income Per Share
| Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| GAAP net loss |
$ | (3,552 | ) | $ | (84 | ) | $ | (10,619 | ) | $ | (1,614 | ) | ||||
| Adjustments to reconcile to Non-GAAP net income: |
||||||||||||||||
| Amortization of purchased intangible assets |
128 | 128 | 257 | 264 | ||||||||||||
| Stock-based compensation |
367 | 140 | 665 | 257 | ||||||||||||
| Change in fair value of contingent liability |
(509 | ) | (68 | ) | (464 | ) | 31 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP Net (Loss) Income (a) |
$ | (3,566 | ) | $ | 116 | $ | (10,161 | ) | $ | (1,062 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Non-GAAP net (loss) income per share attributable to common stockholders |
||||||||||||||||
| Basic |
$ | (0.81 | ) | $ | 0.04 | $ | (2.53 | ) | $ | (0.33 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | (0.81 | ) | $ | 0.01 | $ | (2.53 | ) | $ | (0.33 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding used in computing net (loss) income per share attributable to common stockholders |
||||||||||||||||
| Basic |
4,410 | 3,250 | 4,021 | 3,186 | ||||||||||||
| Add common stock equivalents (b) |
— | 2,306 | — | — | ||||||||||||
| Add preferred shares conversion (c) |
— | 13,971 | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
4,410 | 19,527 | 4,021 | 3,186 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (a) | Non-GAAP earnings are not reserved for payment to preferred shareholders, allowing EPS to be calculated as earnings divided by diluted shares. |
| (b) | Dilutive effect of common stock equivalents to reflect change to share count calculation as a result of non-GAAP adjustments on GAAP net loss to Non-GAAP net income. |
| (c) | Preferred shares as if converted and outstanding for the full quarter. |